ClinicalTrials.gg
CompletedNCT03851705ORION-5Updated Jan 30, 2023Results posted

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

A Phase 3 interventional study of Inclisiran Sodium for injection and Placebo in Homozygous Familial Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 8 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study was a Phase III,A two-part (double-blind placebo-controlled/open-label) multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in subjects with homozygous familial hypercholesterolemia (HoFH).

Read the detailed description

This study had two sequential parts:

  • Part 1: 6-month double-blind period in which subjects were randomized to receive either inclisiran or placebo
  • Part 2: 18-month open-label follow-up period; placebo-treated subjects from Part 1 were transitioned to inclisiran at Day 180 and all subjects who participated in an open-label follow-up period of inclisiran only
02

Conditions studied

  • Homozygous Familial Hypercholesterolemia

Keywords

  • HoFH
03

In context

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

This study's enrollment of 56 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.

Browse Homozygous Familial Hypercholesterolemia studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of HoFH by genetic confirmation or a clinical diagnosis based on a history of an untreated LDL-C concentration >500 mg/dL (13 mmol/L) together with either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents
  2. Stable on a low-fat diet.
  3. Subjects on statins should be receiving a maximally tolerated dose. Maximum tolerated dose is defined as the maximum dose of statin that can be taken on a regular basis without intolerable adverse events.
  4. Subjects not receiving statins must have documented evidence of intolerance to at least two different statins.
  5. Subjects on lipid-lower therapies (such as statin and/or ezetimibe) should be on a stable dose for ≥30 days before screening with no planned medication or dose change during study participation.
  6. Fasting central laboratory LDL-C concentration ≥130 mg/dL (3.4 mmol/L).
  7. Triglyceride concentration \<400 mg/dL (4.5 mmol/L)
  8. No current or planned renal dialysis or renal transplantation
  9. Subjects on a documented regimen of LDL or plasma apheresis will be allowed to continue the apheresis during the study, if needed.
  10. Subjects must be willing and able to give written before initiation of any study-related procedures. The subject should be willing to comply with all required study procedures.
  11. Willing to follow all study procedures including adherence to dietary guidelines, study visits, fasting blood draws, and compliance with study treatment regimens.

Exclusion criteria

Exclusion Criteria:

  1. Use of Mipomersen or Lomitapide therapy within 5 months of screening
  2. Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9
  3. (NYHA) class IV heart failure or last known \<25%
  4. Major adverse cardiovascular event within 3 months prior to randomization
  5. Planned cardiac surgery or revascularization
  6. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization despite anti-hypertensive therapy
  7. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained (ALT), aspartate aminotransferase (AST), elevation >3x , or total >2x upper limit of normal (ULN) at screening confirmed by a repeat measurement at least 1 week apart
  8. Severe concomitant noncardiovascular disease that carries the risk of reducing to less than the duration of the trial
  9. History of that required surgery (excluding local and wide-local excision), radiation therapy and/or commencement of systemic therapy as treatment during the 3 years prior to randomization
  10. Females who are pregnant or nursing, or who are of and unwilling to use at least one acceptable effective method of (eg, oral contraceptives, barrier methods, approved contraceptive implant, long- term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion:

    1. Women >2 years (defined as 1 year or longer since their last menstrual period) AND more than 55 years of age
    2. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of enrolment
    3. Women who are surgically sterilized at least 3 months prior to enrolment
  11. Known history of alcohol and/or drug abuse within 5 years
  12. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:

    1. Subjects who are unable to communicate or to cooperate with the investigator.
    2. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency)
    3. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study)
    4. Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study
    5. Persons directly involved in the conduct of the study
  13. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk (according to investigator's [or delegate] judgment) if he/she participates in the clinical study
  14. Any underlying known disease, or surgical, physical, or medical condition that, in the opinion of the Investigator, might interfere with the interpretation of clinical study results
  15. Treatment with other medicinal products or devices within 30 days or 5 half-lives of the screening visit, whichever is longer
  16. Previous participation in the study
  17. to any of the ingredients of Inclisiran

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Part 1 - Inclisiran

    Participants who received a dose of 300 milligram (mg) inclisiran sodium for injection administered by SC injection on Day 1 and Day 90.

    Drug: Inclisiran Sodium for injection

  • Placebo comparator
    Part 1 - Placebo

    Participants who received a dose of placebos administered by SC injection on Day 1 and Day 90.

    Drug: Placebo · Drug: Placebos

  • Experimental
    Part 2 - Inclisiran

    Participants who received a dose of 300 mg inclisiran sodium for injection administered by SC injection on Day 270, Day 450 and Day 630. In addition, participants who were assigned to the placebo arm in Part 1 will receive a dose of 300 mg inclisiran sodium administered by SC injection on Day 180 after completion of Part 1.

    Drug: Inclisiran Sodium for injection

Interventions

  • Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

    Also known as: ALN-PCSSC; KJX839, ALN-PCSSC

  • DrugPlacebo

    Sterile normal saline (0.9% sodium chloride in water for injection)

  • DrugPlacebos

    Sterile normal saline (0.9% sodium chloride in water for injection)

06

What researchers measure

Primary outcomes

  1. Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150

    Percentage Change in LDL-C levels from Baseline to Day 150

    Time frame: Baseline, Day 150

Secondary outcomes

  1. Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150

    Absolute Change in LDL-C levels (mg/dL) from baseline to Day 150

    Time frame: Baseline, Day 150

  2. Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180

    Percentage Change in LDL-C levels from baseline to subsequent visits on Days 90, 150, and 180

    Time frame: Baseline, Days 90, 150, 180

  3. Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720

    Percentage Change in LDL-C levels from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  4. Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180

    Absolute change in LDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150 and 180 based on the

    Time frame: Baseline, Days 90, 150, 180

  5. Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720

    Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  6. Percent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180

    Percentage Change in PCSK9 from baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  7. Percent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720

    Percentage Change in PCSK9 from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  8. Absolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180

    Absolute Change in PCSK9 from baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  9. Absolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720

    Absolute Change in PCSK9 from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  10. Percent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180

    Percentage change in total cholesterol from baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150 and 180

  11. Absolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180

    Absolute Change in total cholesterol from baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  12. Percent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720

    Percentage change in total cholesterol from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  13. Absolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720

    Absolute Change in total cholesterol from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  14. Percent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180

    Percentage change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180 demonstrated by Mixed Model Repeated Measures statisitical method.

    Time frame: Baseline, Days 90, 150, 180

  15. Percent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 720

    Percentage Change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  16. Absolute Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180

    Absolute change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  17. Absolute Change in Apolipoprotein B (Apo B) From Baseline to Subsequent Visits up to Day 720

    Absolute Change in Apolipoprotein B (Apo B) from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  18. Percent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180

    Percentage change in non-HDL-C levels from baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  19. Percent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720

    Percentage Change in non-HDL-C from Baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  20. Absolute Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180

    Absolute change in non-HDL-C levels from Baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  21. Absolute Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720

    Absolute Change in non-HDL Cholesterol (non-HDL-C) from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720

  22. Individual Responsiveness of Subjects: Part 1

    Individual Responsiveness of Subjects defined as the number of subjects reaching on treatment LDL-C levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL up to Day 180

    Time frame: Days 150, 180

  23. Individual Responsiveness of Subjects: Part 2

    Individual Responsiveness of Subjects defined as the number of subjects reaching on treatment LDL-C levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL up to Day 720

    Time frame: Days 330, 510, 690 and 720

  24. Proportional Responsiveness: Part 1

    Number of participants in each group who attain global lipid targets for their indication

    Time frame: Days 150, 180

  25. Proportional Responsiveness of Subjects: Part 2

    Number of participants in each group who attain global lipid targets for their indication

    Time frame: Days 330, 510, 690 and 720

  26. LDL-C Reduction ≥20% or ≥30% From Baseline: Part 1

    Proportion of subjects in each group with ≥20% or ≥30% LDL-C reduction from Baseline in Part 1 (Days 90, 150, 180)

    Time frame: Baseline, Days 90, 150, 180

  27. LDL-C Reduction ≥20% or ≥30% From Baseline: Part 2

    Proportion of subjects in each group with ≥20% or ≥30% LDL-C reduction from Baseline in Part 2 (Days 330, 510, 690, and 720)

    Time frame: Baseline, Days 330, 510, 690, and 720

  28. Percent Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 180

    Percentage Change in HDL-C levels (mg/dL) from baseline to subsequent visits on Day 90, 150, and 180

    Time frame: Baseline, Days 90, 150, 180

  29. Percent Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 720

    Percentage change in LDL-C levels from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720

  30. Absolute Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 180

    Absolute Change in HDL-C levels (mg/dL) from baseline to subsequent visits on Day 90, 150, and 180

    Time frame: Baseline, Days 90, 150, 180

  31. Absolute Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 720

    Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720

  32. Absolute Change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Subsequent Visits up to Day 180

    Absolute Change in VLDL-C levels from baseline to subsequent visits on Days 90, 150, and 180

    Time frame: Baseline, Days 90, 150, 180

  33. Absolute Change in Very-Low-Density-Lipoprotein Cholesterol Levels (VLDL-C) From Baseline to Subsequent Visits up to Day 720

    Absolute change in VLDL-C levels from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720

  34. Percent Change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Subsequent Visits up to Day 180

    Percentage Change in VLDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150, and 180

    Time frame: Baseline, Days 90, 150, 180

  35. Percent Change in Very-Low-Density-Lipoprotein Cholesterol Levels (VLDL-C) From Baseline to Subsequent Visits up to Day 720

    Percentage change in VLDL-C levels from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720

  36. Absolute Change in Apolipoprotein A-1 (Apo-A1) mg/dL From Baseline to Subsequent Visits up to Day 180

    Absolute Change in Apolipoprotein A-1 (Apo-A1) from baseline to subsequent visits on Days 90, 150, and 180

    Time frame: Baseline, Days 90, 150, 180

  37. Absolute Change Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 720

    Absolute change in Apolipoprotein A-1 (Apo-A1) from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720

  38. Percent Change in Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 180

    Percentage Change in Apolipoprotein A-1 (Apo-A1) from baseline to subsequent visits on Day 90, 150, and 180

    Time frame: Baseline, Days 90, 150, 180

  39. Percent Change Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 720

    Percentage change in Apolipoprotein A-1 (Apo-A1) from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720

  40. Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 180

    Percentage Change in Lp(a) from Baseline to Subsequent Visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  41. Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 720

    Percentage change in Lp(a) from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720

  42. Absolute Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 180

    Absolute Change in Lp(a) from baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  43. Absolute Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 720

    Absolute change in Lp(a) from Baseline to Subsequent Visits up to Day 720

    Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720

  44. Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 180: Part 1

    Percent change in hsCRP from Baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  45. Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 720: Part 2

    Percentage change in hsCRP from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 330, 510 ,690, 720

  46. Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 180: Part 1

    Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) from Baseline to subsequent visits up to Day 180

    Time frame: Baseline, Days 90, 150, 180

  47. Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 720: Part 2

    Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) from baseline to subsequent visits up to Day 720

    Time frame: Baseline, Days 330, 510, 690, 720

  48. Percent Change in Apo-B From Baseline to Day 150

    Percentage change in Apo-B from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.

    Time frame: Baseline, Day 150

  49. Percent Change in Non-HDL-C From Baseline to Day 150

    Percentage Change in non-HDL-C from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.

    Time frame: Baseline, Day 150

  50. Percent Change in Total Cholesterol From Baseline to Day 150

    Percentage change in total cholesterol from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.

    Time frame: Baseline, Day 150

  51. Proportion of Subjects With ≥30% LDL-C Reduction of From Baseline at Day 150

    Number of participants in each group with ≥30% LDL-C reduction from baseline at Day 150 using the Regression Logistic Statistical Model

    Time frame: Baseline, Day 150

07

Results

Posted Nov 10, 2022

Participant flow

Overall, 56 subjects were enrolled and 53 subjects completed through Day 180 (Part 1) and went into the Open-Label period (Part 2), in which 47 subjects completed.

Part 1: Double-Blind Period
Participant flow — Part 1: Double-Blind Period
MilestonePart 1 - InclisiranPart 1 - PlaceboPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Started371900
Completed341900
Not completed3000
Withdrew: Withdrawal by subject2000
Withdrew: Other reason1000
Part 2: Open-Label Period
Participant flow — Part 2: Open-Label Period
MilestonePart 1 - InclisiranPart 1 - PlaceboPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Started003419
Completed002918
Not completed0051
Withdrew: Other reason0001
Withdrew: Death0030
Withdrew: Withdrawal by subject0020

Outcome measures

PrimaryPercent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150

Percentage Change in LDL-C levels from Baseline to Day 150

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage change
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 1502.39 (-19.98 to 24.75)0.70 (-14.03 to 15.44)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · ANCOVA · p = 0.9047 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -1.68 · 95% CI -29.19 to 25.83
SecondaryAbsolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150

Absolute Change in LDL-C levels (mg/dL) from baseline to Day 150

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150
mg/dLPart 1 - PlaceboPart 1 - Inclisiran
Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150-8.82 (-75.19 to 57.55)-2.35 (-36.34 to 31.63)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · ANCOVA · p = 0.8685 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 6.47 · 95% CI -70.11 to 83.05
SecondaryPercent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180

Percentage Change in LDL-C levels from baseline to subsequent visits on Days 90, 150, and 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · Percentage change
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Day 903.3 (-13.0 to 19.6)-8.7 (-20.3 to 2.8)
Day 150-2.9 (-22.6 to 16.9)1.8 (-12.5 to 16.1)
Day 180-1.5 (-17.0 to 14.1)-7.2 (-19.0 to 4.6)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.2347 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -12.1 · 95% CI -32.2 to 8.1
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7058 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 4.6 · 95% CI -19.9 to 29.2
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.5653 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -5.7 · 95% CI -25.5 to 14.1
SecondaryPercent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720

Percentage Change in LDL-C levels from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage change
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720
Percentage changePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-10.1 ± 41.62-9.1 ± 33.99
Day 330-14.4 ± 32.62-4.8 ± 50.45
Day 450-6.7 ± 26.69-4.7 ± 46.92
Day 510-9.3 ± 29.522.4 ± 61.70
Day 630-16.6 ± 20.45-6.6 ± 43.75
Day 690-8.7 ± 32.17-4.2 ± 42.39
Day 720-14.6 ± 26.11-6.2 ± 47.29
SecondaryAbsolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180

Absolute change in LDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150 and 180 based on the

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · mg/dL
Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180
mg/dLPart 1 - PlaceboPart 1 - Inclisiran
Day 903.6 (-39.6 to 46.8)-16.3 (-47.0 to 14.4)
Day 150-17.2 (-70.8 to 36.3)0.5 (-38.3 to 39.2)
Day 180-7.0 (-50.5 to 36.4)-14.5 (-47.5 to 18.5)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.4589 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -19.9 · 95% CI -73.3 to 33.6
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.5956 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 17.7 · 95% CI -48.8 to 84.3
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7861 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -7.5 · 95% CI -62.7 to 47.7
SecondaryAbsolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720

Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · mg/dL
Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720
mg/dLPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-27.3 ± 154.94-17.5 ± 85.85
Day 330-37.2 ± 123.09-17.9 ± 113.10
Day 450-12.3 ± 108.49-19.8 ± 111.41
Day 510-20.9 ± 118.05-2.2 ± 127.13
Day 630-50.5 ± 70.47-14.9 ± 107.90
Day 690-27.9 ± 115.46-8.6 ± 112.93
Day 720-43.5 ± 92.99-11.0 ± 124.27
SecondaryPercent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180

Percentage Change in PCSK9 from baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · Percentage change
Percent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Day 909.1 (-5.1 to 23.3)-53.5 (-63.6 to -43.3)
Day 1504.1 (-14.3 to 22.6)-56.5 (-69.9 to -43.1)
Day 18039.2 (17.0 to 61.5)-53.1 (-70.2 to -35.9)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = <.0001 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -62.6 · 95% CI -80.1 to -45.1
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = <.0001 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -60.6 · 95% CI -83.5 to -37.8
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = <.0001 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -92.3 · 95% CI -120.4 to -64.2
SecondaryPercent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720

Percentage Change in PCSK9 from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage Change
Percent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720
Percentage ChangePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-21.5 ± 55.71-14.4 ± 160.60
Day 330-42.6 ± 32.08-57.0 ± 30.36
Day 450-35.8 ± 37.55-51.1 ± 27.90
Day 510-54.0 ± 23.62-59.4 ± 24.13
Day 630-41.7 ± 29.19-48.1 ± 32.65
Day 690-48.3 ± 22.30-64.3 ± 11.21
Day 720-53.8 ± 16.66-57.6 ± 39.76
SecondaryAbsolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180

Absolute Change in PCSK9 from baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · ug/L
Absolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180
ug/LPart 1 - PlaceboPart 1 - Inclisiran
Day 90-25.8 (-110.3 to 58.6)-342.5 (-403.0 to -282.0)
Day 150-30.7 (-114.4 to 52.9)-335.2 (-396.1 to -274.3)
Day 18088.8 (-1.2 to 178.9)-301.5 (-371.4 to -231.7)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = <.0001 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -316.6 · 95% CI -420.7 to -212.6
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = <.0001 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -304.4 · 95% CI -408.0 to -200.8
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = <.0001 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -390.4 · 95% CI -504.5 to -276.3
SecondaryAbsolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720

Absolute Change in PCSK9 from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · ug/L
Absolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720
ug/LPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-174.7 ± 252.10-234.4 ± 242.25
Day 330-232.1 ± 193.51-392.0 ± 422.93
Day 450-237.5 ± 199.34-387.6 ± 483.81
Day 510-304.8 ± 181.41-381.0 ± 261.04
Day 630-243.6 ± 201.07-303.1 ± 200.37
Day 690-275.5 ± 163.85-441.8 ± 278.87
Day 720-296.8 ± 171.96-413.2 ± 460.33
SecondaryPercent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180

Percentage change in total cholesterol from baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150 and 180
Reported as:
Least squares mean · Percentage Change
Percent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180
Percentage ChangePart 1 - PlaceboPart 1 - Inclisiran
Day 902.0 (-11.0 to 14.9)-5.9 (-15.1 to 3.3)
Day 150-1.5 (-17.2 to 14.1)1.2 (-10.1 to 12.5)
Day 180-1.4 (-13.8 to 11.0)-4.9 (-14.3 to 4.5)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.3299 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -7.9 · 95% CI -23.9 to 8.2
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7778 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 2.7 · 95% CI -16.7 to 22.2
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.6613 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -3.5 · 95% CI -19.2 to 12.3
SecondaryAbsolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180

Absolute Change in total cholesterol from baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · mg/dL
Absolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180
mg/dLPart 1 - PlaceboPart 1 - Inclisiran
Day 903.9 (-40.6 to 48.4)-15.1 (-46.7 to 16.4)
Day 150-10.5 (-65.5 to 44.5)0.6 (-39.2 to 40.4)
Day 180-6.8 (-51.7 to 38.1)-12.6 (-46.6 to 21.3)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.4911 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -19.0 · 95% CI -74.0 to 36.0
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7461 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 11.1 · 95% CI -57.2 to 79.4
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.8370 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -5.9 · 95% CI -62.8 to 51.1
SecondaryPercent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720

Percentage change in total cholesterol from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage Change
Percent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720
Percentage ChangePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-7.4 ± 34.80-4.8 ± 27.31
Day 330-10.9 ± 27.67-1.0 ± 39.20
Day 450-4.2 ± 22.45-2.2 ± 36.05
Day 510-6.4 ± 25.372.8 ± 46.77
Day 630-11.9 ± 17.58-4.8 ± 33.84
Day 690-6.2 ± 26.71-1.9 ± 33.83
Day 720-11.2 ± 21.86-2.9 ± 36.70
SecondaryAbsolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720

Absolute Change in total cholesterol from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · mg/dL
Absolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720
mg/dLPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-24.9 ± 154.60-13.3 ± 90.68
Day 330-35.6 ± 127.19-13.0 ± 115.59
Day 450-7.9 ± 107.22-14.4 ± 113.71
Day 510-17.8 ± 120.400.1 ± 128.73
Day 630-44.5 ± 71.81-14.9 ± 111.50
Day 690-21.6 ± 118.21-6.9 ± 114.58
Day 720-40.4 ± 93.21-8.5 ± 126.48
SecondaryPercent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180

Percentage change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180 demonstrated by Mixed Model Repeated Measures statisitical method.

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · Percentage change
Percent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Day 906.3 (-7.3 to 19.9)-6.4 (-16.1 to 3.3)
Day 1502.8 (-12.5 to 18.1)-0.7 (-11.8 to 10.3)
Day 1804.5 (-8.9 to 17.9)-5.8 (-15.9 to 4.3)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.1371 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -12.7 · 95% CI -29.5 to 4.2
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7100 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -3.5 · 95% CI -22.6 to 15.5
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.2278 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -10.3 · 95% CI -27.2 to 6.6
SecondaryPercent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 720

Percentage Change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage Change
Percent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 720
Percentage ChangePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-0.6 ± 40.91-3.3 ± 28.67
Day 330-7.9 ± 28.56-3.6 ± 34.35
Day 450-1.3 ± 21.62-3.5 ± 35.66
Day 510-3.7 ± 24.211.9 ± 44.49
Day 630-7.3 ± 17.81-6.6 ± 32.97
Day 690-3.7 ± 27.16-5.8 ± 32.38
Day 720-10.4 ± 19.68-8.0 ± 31.93
SecondaryAbsolute Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180

Absolute change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · mg/dL
Absolute Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180
mg/dLPart 1 - PlaceboPart 1 - Inclisiran
Day 9010.0 (-14.5 to 34.5)-9.4 (-26.8 to 8.0)
Day 1503.3 (-24.9 to 31.6)-1.4 (-21.9 to 19.0)
Day 1808.4 (-16.5 to 33.3)-7.4 (-26.2 to 11.4)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.2044 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -19.4 · 95% CI -49.7 to 10.9
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7875 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -4.8 · 95% CI -39.9 to 30.4
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.3193 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -15.8 · 95% CI -47.3 to 15.7
SecondaryAbsolute Change in Apolipoprotein B (Apo B) From Baseline to Subsequent Visits up to Day 720

Absolute Change in Apolipoprotein B (Apo B) from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · mg/dL
Absolute Change in Apolipoprotein B (Apo B) From Baseline to Subsequent Visits up to Day 720
mg/dLPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-1.3 ± 83.72-1.9 ± 51.79
Day 330-11.5 ± 66.78-7.3 ± 56.52
Day 4503.0 ± 53.54-6.9 ± 61.89
Day 510-3.5 ± 58.451.1 ± 70.40
Day 630-15.4 ± 38.17-10.1 ± 57.06
Day 690-10.6 ± 61.77-10.3 ± 54.82
Day 720-22.1 ± 45.29-13.0 ± 55.14
SecondaryPercent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180

Percentage change in non-HDL-C levels from baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · Percentage change
Percent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Day 902.9 (-12.4 to 18.2)-7.2 (-18.1 to 3.6)
Day 150-1.7 (-19.9 to 16.6)1.3 (-11.9 to 14.5)
Day 180-1.1 (-15.6 to 13.3)-6.2 (-17.1 to 4.7)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.2877 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -10.1 · 95% CI -29.0 to 8.8
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7944 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 3.0 · 95% CI -19.7 to 25.7
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.5803 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -5.1 · 95% CI -23.4 to 13.3
SecondaryPercent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720

Percentage Change in non-HDL-C from Baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage Change
Percent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720
Percentage ChangePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-8.4 ± 39.76-7.6 ± 30.95
Day 330-13.1 ± 31.27-2.3 ± 45.56
Day 450-5.5 ± 25.49-3.1 ± 43.73
Day 510-8.0 ± 28.002.0 ± 55.28
Day 630-13.6 ± 18.88-6.5 ± 40.16
Day 690-6.4 ± 30.12-3.6 ± 40.11
Day 720-12.3 ± 23.99-5.0 ± 43.40
SecondaryAbsolute Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180

Absolute change in non-HDL-C levels from Baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · mg/dL
Absolute Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180
mg/dLPart 1 - PlaceboPart 1 - Inclisiran
Day 903.8 (-40.3 to 47.8)-15.3 (-46.5 to 15.9)
Day 150-11.6 (-66.4 to 43.3)0.6 (-39.1 to 40.3)
Day 180-5.7 (-50.2 to 38.9)-12.7 (-46.4 to 21.0)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.4848 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -19.1 · 95% CI -73.6 to 35.3
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7220 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 12.2 · 95% CI -56.0 to 80.3
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.8036 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -7.0 · 95% CI -63.6 to 49.5
SecondaryAbsolute Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720

Absolute Change in non-HDL Cholesterol (non-HDL-C) from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Reported as:
Mean · mg/dL
Absolute Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720
mg/dLPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 270-24.7 ± 157.98-17.1 ± 86.34
Day 330-37.2 ± 127.12-13.9 ± 114.51
Day 450-8.8 ± 109.91-15.8 ± 112.63
Day 510-19.3 ± 120.58-2.4 ± 128.45
Day 630-43.8 ± 70.56-14.7 ± 112.04
Day 690-21.0 ± 116.12-7.8 ± 114.44
Day 720-38.9 ± 91.89-9.3 ± 127.46
SecondaryIndividual Responsiveness of Subjects: Part 1

Individual Responsiveness of Subjects defined as the number of subjects reaching on treatment LDL-C levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL up to Day 180

Time frame:
Days 150, 180
Reported as:
Count of participants · Participants
Individual Responsiveness of Subjects: Part 1
ParticipantsPart 1 - PlaceboPart 1 - Inclisiran
<25 mg/dL- Day 15000
<50 mg/dL- Day 15010
<70 mg/dL- Day 15012
<100 mg/dL- Day 15015
>= 100 mg/dL- Day 1501729
<25 mg/dL- Day 18000
<50 mg/dL- Day 18001
<70 mg/dL- Day 18002
<100 mg/dL- Day 18005
>= 100 mg/dL- Day 1801926
SecondaryIndividual Responsiveness of Subjects: Part 2

Individual Responsiveness of Subjects defined as the number of subjects reaching on treatment LDL-C levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL up to Day 720

Time frame:
Days 330, 510, 690 and 720
Reported as:
Count of participants · Participants
Individual Responsiveness of Subjects: Part 2
ParticipantsPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
<25 mg/dL- Day 33000
<50 mg/dL- Day 33010
<70 mg/dL- Day 33021
<100 mg/dL- Day 33025
>= 100 mg/dL- Day 3301420
<25 mg/dL- Day 51000
<50 mg/dL- Day 51002
<70 mg/dL- Day 51003
< 100 mg/dL- Day 51015
>= 100 mg/dL- Day 5101625
<25 mg/dL- Day 69000
<50 mg/dL- Day 69000
<70 mg/dL- Day 69001
<100 mg/dL- Day 69012
>= 100 mg/dL- Day 6901320
<25 mg/dL- Day 72000
<50 mg/dL- Day 72001
<70 mg/dL- Day 72011
<100 mg/dL- Day 72015
>= 100 mg/dL- Day 7201722
SecondaryProportional Responsiveness: Part 1

Number of participants in each group who attain global lipid targets for their indication

Time frame:
Days 150, 180
Reported as:
Count of participants · Participants
Proportional Responsiveness: Part 1
ParticipantsPart 1 - PlaceboPart 1 - Inclisiran
Day 15013
Day 18003
SecondaryProportional Responsiveness of Subjects: Part 2

Number of participants in each group who attain global lipid targets for their indication

Time frame:
Days 330, 510, 690 and 720
Reported as:
Count of participants · Participants
Proportional Responsiveness of Subjects: Part 2
ParticipantsPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 33022
Day 51004
Day 69001
Day 72012
SecondaryLDL-C Reduction ≥20% or ≥30% From Baseline: Part 1

Proportion of subjects in each group with ≥20% or ≥30% LDL-C reduction from Baseline in Part 1 (Days 90, 150, 180)

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Count of participants · Participants
LDL-C Reduction ≥20% or ≥30% From Baseline: Part 1
ParticipantsPart 1 - InclisiranPart 1 - Placebo
LDL-C >=20%: Day 90414
LDL-C >=20%: Day 15039
LDL-C >=20%: Day 180312
LDL-C >=30%: Day 90313
LDL-C >=30%: Day 15036
LDL-C >=30%: Day 180210
SecondaryLDL-C Reduction ≥20% or ≥30% From Baseline: Part 2

Proportion of subjects in each group with ≥20% or ≥30% LDL-C reduction from Baseline in Part 2 (Days 330, 510, 690, and 720)

Time frame:
Baseline, Days 330, 510, 690, and 720
Reported as:
Count of participants · Participants
LDL-C Reduction ≥20% or ≥30% From Baseline: Part 2
ParticipantsPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
LDL-C >=20%: Day 330513
LDL-C >=20%: Day 510611
LDL-C >=20%: Day 690811
LDL-C >=20%: Day 720713
LDL-C >=30%: Day 33048
LDL-C >=30%: Day 51049
LDL-C >=30%: Day 69045
LDL-C >=30%: Day 72058
SecondaryPercent Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 180

Percentage Change in HDL-C levels (mg/dL) from baseline to subsequent visits on Day 90, 150, and 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · Percentage change
Percent Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 180
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Day 90-1.1 (-8.6 to 6.5)1.4 (-4.0 to 6.7)
Day 1502.3 (-8.0 to 12.6)3.6 (-3.9 to 11.1)
Day 180-1.9 (-9.8 to 6.0)1.5 (-4.5 to 7.6)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.6028 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 2.4 · 95% CI -6.8 to 11.7
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.8428 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 1.3 · 95% CI -11.5 to 14.0
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.4946 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 3.4 · 95% CI -6.6 to 13.4
SecondaryPercent Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 720

Percentage change in LDL-C levels from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage change
Percent Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 720
Percentage changePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 3303.2 ± 13.094.3 ± 16.45
Day 4501.6 ± 12.264.8 ± 17.81
Day 5102.9 ± 19.837.9 ± 17.75
Day 630-2.0 ± 14.810.5 ± 15.81
Day 690-2.4 ± 19.174.5 ± 20.31
Day 720-3.6 ± 14.904.1 ± 16.99
SecondaryAbsolute Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 180

Absolute Change in HDL-C levels (mg/dL) from baseline to subsequent visits on Day 90, 150, and 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · mg/dL
Absolute Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 180
mg/dLPart 1 - PlaceboPart 1 - Inclisiran
Day 90-0.0 (-3.4 to 3.4)0.2 (-2.2 to 2.6)
Day 1501.0 (-3.5 to 5.4)-0.0 (-3.2 to 3.2)
Day 180-1.2 (-4.5 to 2.1)0.0 (-2.5 to 2.5)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.9237 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 0.2 · 95% CI -4.0 to 4.4
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7177 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -1.0 · 95% CI -6.5 to 4.5
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.5416 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 1.3 · 95% CI -2.9 to 5.4
SecondaryAbsolute Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 720

Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 330, 450, 510, 630, 690, and 720
Reported as:
Mean · mg/dL
Absolute Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 720
mg/dLPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 3301.6 ± 6.050.9 ± 6.85
Day 4500.9 ± 6.041.4 ± 8.53
Day 5101.5 ± 8.782.5 ± 7.86
Day 630-0.7 ± 7.35-0.2 ± 7.70
Day 690-0.6 ± 9.571.0 ± 8.31
Day 720-1.5 ± 7.220.8 ± 7.34
SecondaryAbsolute Change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Subsequent Visits up to Day 180

Absolute Change in VLDL-C levels from baseline to subsequent visits on Days 90, 150, and 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · mg/dL
Absolute Change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Subsequent Visits up to Day 180
mg/dLPart 1 - PlaceboPart 1 - Inclisiran
Day 900.6 (-2.8 to 4.0)1.6 (-0.9 to 4.0)
Day 1503.0 (-1.3 to 7.3)0.4 (-2.7 to 3.4)
Day 1801.8 (-3.0 to 6.5)1.5 (-2.1 to 5.1)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.6497 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 1.0 · 95% CI -3.2 to 5.2
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.3209 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -2.6 · 95% CI -7.9 to 2.6
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.9294 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -0.3 · 95% CI -6.3 to 5.7
SecondaryAbsolute Change in Very-Low-Density-Lipoprotein Cholesterol Levels (VLDL-C) From Baseline to Subsequent Visits up to Day 720

Absolute change in VLDL-C levels from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 330, 450, 510, 630, 690, and 720
Reported as:
Mean · mg/dL
Absolute Change in Very-Low-Density-Lipoprotein Cholesterol Levels (VLDL-C) From Baseline to Subsequent Visits up to Day 720
mg/dLPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 3300.0 ± 9.382.7 ± 8.03
Day 4501.1 ± 5.844.4 ± 8.91
Day 510-0.9 ± 4.76-0.2 ± 8.85
Day 6306.7 ± 13.760.2 ± 8.39
Day 6906.9 ± 14.580.8 ± 9.34
Day 7202.5 ± 6.811.7 ± 9.06
SecondaryPercent Change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Subsequent Visits up to Day 180

Percentage Change in VLDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150, and 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · Percentage change
Percent Change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Subsequent Visits up to Day 180
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Day 900.6 (-17.4 to 18.7)11.9 (-1.0 to 24.9)
Day 15016.3 (-1.6 to 34.1)4.9 (-7.8 to 17.6)
Day 18010.0 (-13.4 to 33.5)12.3 (-5.3 to 29.9)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.3105 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 11.3 · 95% CI -10.8 to 33.4
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.3018 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -11.4 · 95% CI -33.3 to 10.5
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.8755 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): 2.3 · 95% CI -27.0 to 31.6
SecondaryPercent Change in Very-Low-Density-Lipoprotein Cholesterol Levels (VLDL-C) From Baseline to Subsequent Visits up to Day 720

Percentage change in VLDL-C levels from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage Change
Percent Change in Very-Low-Density-Lipoprotein Cholesterol Levels (VLDL-C) From Baseline to Subsequent Visits up to Day 720
Percentage ChangePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 3306.8 ± 38.9220.8 ± 57.44
Day 4507.1 ± 28.8623.9 ± 46.36
Day 5102.1 ± 33.457.1 ± 43.16
Day 63025.1 ± 44.226.2 ± 46.21
Day 69026.5 ± 51.7911.4 ± 59.86
Day 72013.9 ± 33.2612.4 ± 50.37
SecondaryAbsolute Change in Apolipoprotein A-1 (Apo-A1) mg/dL From Baseline to Subsequent Visits up to Day 180

Absolute Change in Apolipoprotein A-1 (Apo-A1) from baseline to subsequent visits on Days 90, 150, and 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · mg/dL
Absolute Change in Apolipoprotein A-1 (Apo-A1) mg/dL From Baseline to Subsequent Visits up to Day 180
mg/dLPart 1 - PlaceboPart 1 - Inclisiran
Day 902.6 (-5.2 to 10.3)0.6 (-4.9 to 6.1)
Day 1504.0 (-6.5 to 14.6)-1.4 (-9.1 to 6.3)
Day 1801.4 (-6.9 to 9.8)-1.3 (-7.7 to 5.1)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.6848 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -1.9 · 95% CI -11.5 to 7.6
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.4075 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -5.4 · 95% CI -18.5 to 7.6
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.5998 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -2.8 · 95% CI -13.4 to 7.8
SecondaryAbsolute Change Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 720

Absolute change in Apolipoprotein A-1 (Apo-A1) from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 330, 450, 510, 630, 690, and 720
Reported as:
Mean · mg/dL
Absolute Change Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 720
mg/dLPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 3300.9 ± 14.141.2 ± 13.85
Day 4504.9 ± 14.044.7 ± 16.59
Day 5106.7 ± 20.397.8 ± 16.32
Day 6305.4 ± 15.591.3 ± 13.11
Day 6906.9 ± 17.079.3 ± 15.69
Day 7203.9 ± 15.156.9 ± 11.30
SecondaryPercent Change in Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 180

Percentage Change in Apolipoprotein A-1 (Apo-A1) from baseline to subsequent visits on Day 90, 150, and 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · Percentage change
Percent Change in Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 180
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Day 901.6 (-4.5 to 7.6)0.6 (-3.7 to 4.9)
Day 1503.0 (-5.1 to 11.1)0.4 (-5.5 to 6.3)
Day 1801.6 (-5.0 to 8.3)-1.0 (-6.1 to 4.1)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.7958 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -1.0 · 95% CI -8.4 to 6.5
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.6003 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -2.6 · 95% CI -12.7 to 7.4
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.5352 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -2.6 · 95% CI -11.0 to 5.8
SecondaryPercent Change Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 720

Percentage change in Apolipoprotein A-1 (Apo-A1) from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage change
Percent Change Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 720
Percentage changePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 3300.4 ± 11.371.3 ± 10.80
Day 4504.4 ± 10.763.9 ± 12.71
Day 5106.2 ± 17.006.8 ± 13.40
Day 6305.4 ± 11.110.8 ± 9.93
Day 6905.6 ± 13.927.2 ± 12.17
Day 7203.5 ± 11.715.5 ± 9.27
SecondaryPercent Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 180

Percentage Change in Lp(a) from Baseline to Subsequent Visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · Percentage change
Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 180
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Day 904.3 (-6.2 to 14.7)-4.6 (-12.2 to 2.9)
Day 15015.2 (-6.8 to 37.2)-3.8 (-19.8 to 12.2)
Day 1804.9 (-6.5 to 16.4)-4.8 (-13.5 to 4.0)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.1716 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -8.9 · 95% CI -21.8 to 4.0
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.1671 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -19.0 · 95% CI -46.2 to 8.2
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.1808 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -9.7 · 95% CI -24.2 to 4.7
SecondaryPercent Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 720

Percentage change in Lp(a) from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 330, 450, 510, 630, 690, and 720
Reported as:
Mean · Percentage change
Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 720
Percentage changePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 3302.5 ± 33.15-1.4 ± 26.69
Day 4503.4 ± 45.120.2 ± 26.42
Day 5108.3 ± 44.7413.4 ± 39.37
Day 630-8.4 ± 32.651.7 ± 29.43
Day 690-10.7 ± 34.02-5.3 ± 27.44
Day 720-11.4 ± 51.06-3.1 ± 45.08
SecondaryAbsolute Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 180

Absolute Change in Lp(a) from baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Least squares mean · nmol/L
Absolute Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 180
nmol/LPart 1 - PlaceboPart 1 - Inclisiran
Day 905.8 (-9.4 to 20.9)-3.8 (-14.7 to 7.1)
Day 1503.9 (-12.8 to 20.6)-5.6 (-17.7 to 6.5)
Day 1801.2 (-12.4 to 14.7)-5.1 (-15.3 to 5.2)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.3077 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -9.6 · 95% CI -28.3 to 9.1
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.3628 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -9.4 · 95% CI -30.1 to 11.2
  • Part 1 - Placebo vs Part 1 - Inclisiran · Mixed Model Repeated Measures · p = 0.4669 (The a priori threshold for statistical significance was \<0.05 (two-sided)) · Mean difference (final values): -6.2 · 95% CI -23.2 to 10.8
SecondaryAbsolute Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 720

Absolute change in Lp(a) from Baseline to Subsequent Visits up to Day 720

Time frame:
Baseline, Days 330, 450, 510, 630, 690, and 720
Reported as:
Mean · nmol/L
Absolute Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 720
nmol/LPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 330-3.1 ± 36.71-5.2 ± 30.65
Day 450-3.8 ± 47.483.1 ± 41.28
Day 51014.5 ± 50.2518.4 ± 53.31
Day 630-2.4 ± 31.1813.7 ± 50.77
Day 690-5.3 ± 26.525.8 ± 26.46
Day 720-6.0 ± 48.125.2 ± 30.44
SecondaryPercent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 180: Part 1

Percent change in hsCRP from Baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Mean · Percentage Change
Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 180: Part 1
Percentage ChangePart 1 - InclisiranPart 1 - Placebo
Day 9041.2 ± 243.9442.0 ± 170.41
Day 150230.8 ± 640.11126.9 ± 380.15
Day 180115.1 ± 490.1745.2 ± 143.24
SecondaryPercent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 720: Part 2

Percentage change in hsCRP from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 330, 510 ,690, 720
Reported as:
Mean · Percentage Change
Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 720: Part 2
Percentage ChangePart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 330178.9 ± 657.6717.3 ± 73.29
Day 510266.7 ± 936.7664.7 ± 204.54
Day 69029.0 ± 125.1837.5 ± 92.40
Day 72049.6 ± 167.1638.60 ± 112.57
SecondaryAbsolute Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 180: Part 1

Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) from Baseline to subsequent visits up to Day 180

Time frame:
Baseline, Days 90, 150, 180
Reported as:
Mean · mg/L
Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 180: Part 1
mg/LPart 1 - PlaceboPart 1 - Inclisiran
Day 90-3.2 ± 9.460.7 ± 4.25
Day 1500.5 ± 15.071.1 ± 6.51
Day 180-3.8 ± 9.330.2 ± 3.75
SecondaryAbsolute Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 720: Part 2

Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) from baseline to subsequent visits up to Day 720

Time frame:
Baseline, Days 330, 510, 690, 720
Reported as:
Mean · mg/L
Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 720: Part 2
mg/LPart 2 - Placebo-InclisiranPart 2 - Inclisiran-Inclisiran
Day 330-4.0 ± 9.98-0.4 ± 2.81
Day 510-3.4 ± 10.070.9 ± 4.75
Day 690-4.7 ± 10.210.7 ± 3.94
Day 720-3.7 ± 9.86-0.2 ± 4.25
SecondaryPercent Change in Apo-B From Baseline to Day 150

Percentage change in Apo-B from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage change
Percent Change in Apo-B From Baseline to Day 150
Percentage changePart 1 - PlaceboPart 1 - Inclisiran
Percent Change in Apo-B From Baseline to Day 1503.55 (-13.60 to 20.71)-0.75 (-11.50 to 9.99)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · ANCOVA · p = 0.6814 · Mean difference (final values): -4.31 · 95% CI -24.88 to 16.27
SecondaryPercent Change in Non-HDL-C From Baseline to Day 150

Percentage Change in non-HDL-C from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage Change
Percent Change in Non-HDL-C From Baseline to Day 150
Percentage ChangePart 1 - PlaceboPart 1 - Inclisiran
Percent Change in Non-HDL-C From Baseline to Day 1502.46 (-19.12 to 24.05)0.37 (-12.68 to 13.42)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · ANCOVA · p = 0.8725 · Mean difference (final values): -2.10 · 95% CI -27.70 to 23.51
SecondaryPercent Change in Total Cholesterol From Baseline to Day 150

Percentage change in total cholesterol from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage Change
Percent Change in Total Cholesterol From Baseline to Day 150
Percentage ChangePart 1 - PlaceboPart 1 - Inclisiran
Percent Change in Total Cholesterol From Baseline to Day 1501.51 (-16.49 to 19.50)0.71 (-10.39 to 11.82)
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · ANCOVA · p = 0.9425 · Mean difference (final values): -0.79 · 95% CI -22.30 to 20.72
SecondaryProportion of Subjects With ≥30% LDL-C Reduction of From Baseline at Day 150

Number of participants in each group with ≥30% LDL-C reduction from baseline at Day 150 using the Regression Logistic Statistical Model

Time frame:
Baseline, Day 150
Reported as:
Count of participants · Participants
Proportion of Subjects With ≥30% LDL-C Reduction of From Baseline at Day 150
ParticipantsPart 1 - PlaceboPart 1 - Inclisiran
Proportion of Subjects With ≥30% LDL-C Reduction of From Baseline at Day 15036
Statistical analysis
  • Part 1 - Placebo vs Part 1 - Inclisiran · Regression, Logistic · Odds ratio (or): 1.1 · 95% CI 0.2 to 5.2

Adverse events

Collected over Adverse Events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of approximately 2 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Inclisiran0/37 (0%)2/37 (5.4%)12/37 (32.4%)
Part 1: Placebo0/19 (0%)1/19 (5.3%)6/19 (31.6%)
Part 1:All Patients0/56 (0%)3/56 (5.4%)18/56 (32.1%)
Part 2: Inclisiran3/53 (5.7%)11/53 (20.8%)29/53 (54.7%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPart 1: InclisiranPart 1: PlaceboPart 1:All PatientsPart 2: Inclisiran
Family stressSocial circumstances0/371/191/560/53
Aortic valve stenosisCardiac disorders0/370/190/562/53
Pneumonia viralInfections and infestations0/370/190/562/53
Non-cardiac chest painGeneral disorders1/370/191/560/53
EndocarditisInfections and infestations1/370/191/561/53
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/370/191/560/53
Angina unstableCardiac disorders0/370/190/561/53
Arteriosclerosis coronary arteryCardiac disorders0/370/190/561/53
Cardiac failureCardiac disorders0/370/190/561/53
Coronary artery diseaseCardiac disorders0/370/190/561/53
Most frequent other events
Showing 10 of 74
Most frequent other events
EventPart 1: InclisiranPart 1: PlaceboPart 1:All PatientsPart 2: Inclisiran
Respiratory tract infection viralInfections and infestations2/372/194/562/53
Corona virus infectionInfections and infestations0/370/190/564/53
International normalised ratio increasedInvestigations0/370/190/563/53
DiarrhoeaGastrointestinal disorders2/370/192/560/53
PyrexiaGeneral disorders2/370/192/560/53
AnaemiaBlood and lymphatic system disorders1/371/192/561/53
AstheniaGeneral disorders0/371/191/560/53
PharyngitisInfections and infestations0/371/191/560/53
TonsillitisInfections and infestations1/371/192/560/53
Alanine aminotransferase increasedInvestigations0/371/191/561/53

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)InclisiranPlaceboTotal
<=18 years000
Between 18 and 65 years341953
>=65 years303
Sex: Female, Male
Sex: Female, Male(Participants)InclisiranPlaceboTotal
Female231134
Male14822
Race (NIH/OMB)
Race (NIH/OMB)(Participants)InclisiranPlaceboTotal
American Indian or Alaska Native000
Asian628
Native Hawaiian or Other Pacific Islander000
Black or African American000
White311748
More than one race000
Unknown or Not Reported000
08

Study locations

13 sites
  • (50852-001) Queen Mary Hospital
    Hong Kong, Hong Kong
  • (50972-001) Hadassah Hospital Lipid Research Ein Kerem
    Jerusalem, 91120, Israel
  • (50007-001) Research Institute of Complex Issues of Cardiovascular Diseases
    Kemerovo, 650002, Russian Federation
  • (50007-003) National Medical Research Centre of Cardiology
    Moscow, 121552, Russian Federation
  • (50007-002) Hospital for War Veterans
    Saint Petersburg, 193079, Russian Federation
  • (50381-001) Clinical Center of Serbia
    Belgrad, 11000, Serbia
  • (50027-001) Johannesburg Hospital
    Johannesburg, 2193, South Africa
  • (50886-001) Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • (50090-002) University of Health Sciences
    Etlik, 06010, Turkey
  • (50090-003) Istanbul University
    Istanbul, 34093, Turkey
  • (50090-001) Ege Universitesi
    İzmir, 35040, Turkey
  • (50380-002) IMunicipal Non-commercial Enterprise "Ivano-Frankivsk Regional Clinical Cardiology Center Ivano-Frankivsk Regional Council"
    Ivano-Frankivs'k, 76018, Ukraine
  • (50380-001) National Scientific Center
    Kyiv, 03680, Ukraine
09

References and documents

Publications

  • Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053. PubMed 33990512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Mar 2020, 12 months.

Results were first posted in Nov 2022, 2 years 8 months after primary completion. A results delay was requested in Nov 2020.

Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2019
First posted
Feb 22, 2019
StartActual
Feb 6, 2019
Primary completionActual
Mar 2, 2020
CompletionActual
Sep 9, 2021
Results delay requested
Nov 11, 2020
Results first posted
Nov 10, 2022
Last update
Jan 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03851705
Responsible party
Sponsor
First posted
Feb 22, 2019
Start date
Feb 6, 2019
Primary completion
Mar 2, 2020
Completion
Sep 9, 2021
Results posted
Nov 10, 2022
Last update
Jan 30, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion